NCT03251716

Berberine Treat Metabolic Syndrome in Schizophrenia

Berberine in the Treatment of Metabolic Syndrome : an Open Label Clinical Study in Female Schizophrenia Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Tianjin Anding Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

In early clinical study investigators confirmed that berberine could prevent glucose and lipid metabolism disorder in schizophrenia, so investigators intend to verify the effect and safety of berberine in treatment for metabolic syndrome in schizophrenia.

Detailed description

This study is an open lable clinical intervention trial, include 30 female subjects with diagnosis of schizophrenia and metabolic syndrome.Participants will be given berberine（ 300mgTID） as an add-on therapy lasting 8 weeks.

Conditions

• Metabolic Syndrome
• Female
• Schizophrenia

Interventions

Type	Name	Description
DRUG	berberine	berberine 300mg TID add-on for berberine adjunctive group

Timeline

• Start date: 2015-01-01
• Primary completion: 2017-10-30
• Completion: 2017-12-30
• First posted: 2017-08-16
• Last updated: 2018-04-25

Locations

1 site across 1 country: China